HLX37 / Fosun Pharma - LARVOL DELTA

A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=254 | Active, not recruiting | Sponsor: Shanghai Henlius Biotech

New P1 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

The Investigational New Drug application of HLX37 (recombinant humanised anti-PD-L1 and anti-VEGF bispecific antibody) for the treatment of patients with advanced/metastatic solid tumours approved by the National Medical Products Administration (NMPA) (HKEXnews)

New trial • Solid Tumor

A novel anti-PD-L1/VEGF bispecific antibody (HLX37) with immune checkpoint inhibition, anti-angiogenic, and antineoplastic activities (AACR 2025) - "HLX37 is an anti-PD-L1/VEGF bispecific antibody with immune checkpoint inhibitory, anti-angiogenic, and antineoplastic properties. It demonstrated strong preclinical efficacy and a favorable safety profile, with enhanced tumor enrichment. It holds promising potential for further application in various types of tumors."

Checkpoint inhibition • Breast Cancer • Colon Cancer • Colorectal Cancer • Hepatocellular Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Salivary Gland Cancer • Solid Tumor • Squamous Cell Carcinoma • KDR

Henlius to Present Three Preclinical Studies at AACR 2025 (Henlius Press Release) - "The American Association for Cancer Research 2025 Annual Meeting (AACR 2025) is set to take place from April 25 to April 30 in Chicago, the United States. Henlius will share three latest preclinical research results from its pipeline programs. The results to be presented include the novel anti-PD-L1/VEGF bispecific antibody HLX37, a novel KAT6A/B inhibitors with best-in-class potential, and a first-in-class ADC linker-payload featuring a highly differentiated killing mechanism."

Preclinical • Oncology